Mohamed Bouattour

机构：Centre National de la Recherche Scientifique, Inserm, Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris, Centre de Recherche sur l'Inflammation · ORCID：0000-0002-3919-4135

发表论文 269 篇 · 总被引 11134 次 · h-index 38

代表论文

• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 72)
• Real‐World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort (2025 · Liver International · 被引 8)
• Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis (2025 · JHEP Reports · 被引 3)
• Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 2)
• 1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC (2025 · Annals of Oncology · 被引 2)
• Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study (2026 · Journal of Hepatology · 被引 1)